Form 8-K - Current report:
SEC Accession No. 0000950170-22-009657
Filing Date
2022-05-12
Accepted
2022-05-12 16:08:12
Documents
13
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20220512.htm   iXBRL 8-K 54478
2 EX-99.1 kzr-ex99_1.htm EX-99.1 94175
  Complete submission text file 0000950170-22-009657.txt   276640

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kzr-20220512_pre.xml EX-101.PRE 9857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kzr-20220512_lab.xml EX-101.LAB 13342
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kzr-20220512.xsd EX-101.SCH 2511
7 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20220512_htm.xml XML 4713
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 22917836
SIC: 2834 Pharmaceutical Preparations